%0 Journal Article %T Efficacies of the new Paclitaxel-eluting Coroflex Please£¿ Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please£¿ and Taxus£¿ (ECO-PLEASANT) trial: study rationale and design %A Jae-Bin Seo %A Hui-Kyung Jeon %A Kyung-Woo Park %A Jong-Seon Park %A Jang-Ho Bae %A Sang-Wook Kim %A Keon-Woong Moon %A Jae-Woong Choi %A Sang-Gon Lee %A Woo-Young Chung %A Tae-Jin Youn %A Soo-Joong Kim %A Doo-Il Kim %A Byung-Ok Kim %A Min-Su Hyon %A Keum-Soo Park %A Tae-Joon Cha %A Hweung-Kon Hwang %A Seung-Ho Hur %A Hyo-Soo Kim %J Trials %D 2009 %I BioMed Central %R 10.1186/1745-6215-10-98 %X In the comparison of Efficacy between COroflex PLEASe£¿ ANd Taxus£¿ stent(ECO-PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the either type of Coroflex Please£¿ stent and Taxus Liberte£¿ stent via web-based randomization. The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and angiographic efficacy endpoints.The ECO-PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex Please£¿ versus Taxus Liberte£¿ stent. On the basis of this trial, we will be able to find out whether the Coroflex Please£¿ stent is non-inferior to Taxus Liberte£¿ stent or not.ClinicalTrials.gov number, NCT00699543.Previous randomized trials have shown the efficacy of a slow-release polymeric sirolimus-eluting stent (Cypher£¿, Cordis, Warren, NJ, USA), paclitaxel-eluting stent (Taxus£¿, Boston Scientific, Natick, MA, USA), and zotarolimus-eluting stent (Endeavor£¿, Medtronic, Minneapolis, MN, USA) over bare metal stents in reducing neointimal hyperplasia, late luminal loss, and angiographic restenosis leading to decreased target lesion revascularization [1-11] The Paclitaxel-eluting Coroflex Please£¿ stent is a newly developed drug eluting stent using the Coroflex£¿ stent platform combined with the drug paclitaxel contained in a polymer coating[12]In the PECOPS I, which was one-arm observational study, the results of Coroflex Please£¿ stent were within the range of other Paclitaxel-eluting coronary stents [12,13] Compared with binary restenosis rate of 7.9% in Taxus IV trial, Coroflex£¿ Please stent showed 7.8% of restenosis rate[7] The 3.1% of 30 day MACE rate is within the range of other trials with stents eluting Paclitaxel or Sirolimus. The 6 month MACE rates in PECOPS I were 8.0%, which was similar to 7.8%, and 8.5% in Taxus II MR and SR, respectively[6] In Taxus IV, 9 month f %U http://www.trialsjournal.com/content/10/1/98